PubRank

Clinical lymphoma & myeloma (Clin Lymphoma Myeloma)

Journal PubWeight™ 248.65‹?›

Top papers

Rank Title Year PubWeight™‹?›
1 Non-Hodgkin's lymphoma involving the liver: clinical and therapeutic considerations. 2006 1.70
2 Treatment of multiple myeloma: a comprehensive review. 2009 1.63
3 Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma? 2008 1.58
4 Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma. 2006 1.47
5 Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. 2006 1.44
6 Cardiac involvement with lymphoma: a review of the literature. 2008 1.43
7 The effect of radiologic imaging studies on the risk of secondary malignancy development in patients with Hodgkin lymphoma. 2007 1.39
8 Idiopathic cholestasis as a paraneoplastic phenomenon in Hodgkin's lymphoma. 2006 1.25
9 Acute coronary syndromes complicating the first infusion of rituximab. 2008 1.23
10 Hodgkin lymphoma: an update on its biology with new insights into classification. 2009 1.21
11 Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin. 2008 1.17
12 Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas. 2007 1.14
13 An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma. 2008 1.13
14 Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis. 2009 1.13
15 Association between renal cell carcinoma and plasma cell dyscrasias: a case series of six patients. 2008 1.13
16 Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia. 2009 1.13
17 Incidence of lymphoma in patients with rheumatoid arthritis: a systematic review of the literature. 2008 1.13
18 Treatment of patients with myeloma with comorbid conditions: considerations for the clinician. 2008 1.12
19 Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. 2009 1.11
20 Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. 2009 1.10
21 Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. 2006 1.09
22 Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. 2006 1.09
23 Practical considerations for multiple myeloma: an overview of recent data and current options. 2008 1.09
24 Assessment of bone marrow response in Waldenström's macroglobulinemia. 2009 1.08
25 Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. 2007 1.07
26 Minimal residual disease quantitation in acute myeloid leukemia. 2009 1.07
27 T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity? 2009 1.05
28 T-cell prolymphocytic leukemia. 2009 1.05
29 Promoter hypermethylation of the MEG3 (DLK1/MEG3) imprinted gene in multiple myeloma. 2008 1.04
30 Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. 2006 1.04
31 Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy. 2006 1.04
32 Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. 2009 1.03
33 Multiple myeloma involving the cavernous sinus: a report of 3 cases and response to bortezomib. 2007 1.03
34 Liver involvement in multiple myeloma. 2007 1.02
35 Primary central nervous system mucosa-associated lymphoid tissue lymphoma: case report and literature review. 2009 1.02
36 The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma. 2008 1.02
37 Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapy. 2009 1.02
38 Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma. 2007 1.02
39 Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma. 2008 1.02
40 Targeting B-lymphocyte stimulator/B-cell activating factor and a proliferation-inducing ligand in hematologic malignancies. 2006 1.01
41 Response to bortezomib and activation of osteoblasts in multiple myeloma. 2006 1.01
42 Mantle cell lymphoma: biological insights and treatment advances. 2009 1.00
43 Burkitt lymphoma/leukemia: improving prognosis. 2009 0.99
44 Regulatory T cells and multiple myeloma. 2008 0.98
45 Current standards for first-line therapy of multiple myeloma. 2007 0.98
46 Gene hypermethylation in multiple myeloma: lessons from a cancer pathway approach. 2008 0.98
47 Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12. 2007 0.97
48 Expanding therapeutic options in mantle cell lymphoma. 2007 0.97
49 Primary central nervous system marginal zone B-cell lymphoma of the Basal Ganglia mimicking low-grade glioma: a case report and review of the literature. 2008 0.97
50 Bortezomib-induced tumor lysis syndrome in multiple myeloma. 2006 0.97
Next 50